



**Washington State Health Care Authority  
Prescription Drug Program**

626 8<sup>th</sup> Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

12/28/2020

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective January 1, 2021:

<b>Antidepressants – Other reviewed 6/20/2018</b>		<b>Agency Coverage</b>	
<b>Ingredient Name</b>	<b>Label Name of Preferred Product</b>	<b>L&amp;I</b>	<b>UMP</b>
bupropion HCL	bupropion HCL tablet	Yes	Yes
	bupropion HCL ER tablet	Yes	Yes
	bupropion HCL SR tablet	Yes	Yes
	bupropion HCL XL tablet	Yes	Yes
mirtazapine	mirtazapine tablet	Yes	Yes
	mirtazapine ODT tablet dispersible	Yes	Yes

The effect of this recommendation is no change to the PDL.

<b>Antidepressants – SNRI</b>		<b>Agency Coverage</b>	
<b>Ingredient Name</b>	<b>Label Name of Preferred Product</b>	<b>L&amp;I</b>	<b>UMP</b>
duloxetine HCL	duloxetine HCL capsule	Yes	Yes
venlafaxine HCL	venlafaxine HCL tablet	Yes	Yes
	venlafaxine HCL ER capsule	Yes	Yes

The effect of this recommendation is no change to the PDL.

<b>Antidepressants – SSRI</b>		<b>Agency Coverage</b>	
<b>Ingredient Name</b>	<b>Label Name of Preferred Product</b>	<b>L&amp;I</b>	<b>UMP</b>
citalopram HBR	citalopram HBR tablet	Yes	Yes
escitalopram oxalate	escitalopram oxalate tablet	Yes	Yes
fluoxetine HCL	fluoxetine DR capsule	Yes	Yes
	fluoxetine HCL capsule	Yes	Yes
	fluoxetine HCL solution	Yes	Yes
fluvoxamine maleate	fluvoxamine maleate tablet	Yes	Yes
paroxetine HCL	paroxetine HCL tablet	Yes	Yes
sertraline HCL	sertraline HCL tablet	Yes	Yes

The effect of this recommendation is no change to the PDL.

<b>Diabetes – Long-acting Insulins reviewed 8/15/2018</b>		<b>Agency Coverage</b>	
<b>Ingredient Name</b>	<b>Label Name of Preferred Product</b>	<b>L&amp;I</b>	<b>UMP</b>
insulin glargine	Basaglar Kwikpen	Not participating	Yes

The effect of this recommendation is no change to the WA PDL.

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at [leta.evaskus@hca.wa.gov](mailto:leta.evaskus@hca.wa.gov).

Sincerely,

A handwritten signature in cursive script that reads "Donna Sullivan".

Donna Sullivan  
Chief Pharmacy Officer  
Clinical Quality and Care Transformation  
Washington State Health Care Authority